Analysts expect that Bruker (NASDAQ:BRKR) will post $418.11 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Bruker’s earnings, with the lowest sales estimate coming in at $410.40 million and the highest estimate coming in at $433.40 million. Bruker reported sales of $384.90 million during the same quarter last year, which suggests a positive year-over-year growth rate of 8.6%. The company is scheduled to report its next quarterly earnings results on Wednesday, May 2nd.
According to Zacks, analysts expect that Bruker will report full-year sales of $418.11 million for the current year, with estimates ranging from $1.87 billion to $1.89 billion. For the next year, analysts expect that the company will report sales of $1.96 billion per share, with estimates ranging from $1.92 billion to $1.98 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Bruker.
Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 8th. The medical research company reported $0.51 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.02. Bruker had a net margin of 4.45% and a return on equity of 26.68%. The company had revenue of $530.50 million for the quarter, compared to analyst estimates of $506.74 million. During the same quarter in the prior year, the business posted $0.46 EPS. The firm’s revenue was up 12.8% compared to the same quarter last year.
BRKR has been the subject of several analyst reports. Zacks Investment Research lowered shares of Bruker from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Cowen reaffirmed a “hold” rating and issued a $35.00 price objective on shares of Bruker in a research note on Thursday, December 21st. BidaskClub lowered Bruker from a “buy” rating to a “hold” rating in a research note on Saturday, February 10th. Evercore ISI began coverage on Bruker in a research note on Wednesday, January 3rd. They issued an “in-line” rating and a $36.00 price objective on the stock. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $35.00 price objective on shares of Bruker in a research note on Thursday, December 14th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $32.62.
NASDAQ:BRKR traded down $1.12 on Wednesday, hitting $29.12. The stock had a trading volume of 640,342 shares, compared to its average volume of 588,352. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.66 and a current ratio of 2.59. The firm has a market cap of $4,717.64, a price-to-earnings ratio of 24.79, a price-to-earnings-growth ratio of 2.01 and a beta of 1.12. Bruker has a 1 year low of $21.83 and a 1 year high of $36.53.
The business also recently announced a quarterly dividend, which was paid on Friday, March 23rd. Investors of record on Tuesday, March 6th were issued a dividend of $0.04 per share. The ex-dividend date was Monday, March 5th. This represents a $0.16 annualized dividend and a dividend yield of 0.55%. Bruker’s payout ratio is currently 13.22%.
Several large investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Bruker by 7.1% during the 4th quarter. BlackRock Inc. now owns 5,173,860 shares of the medical research company’s stock valued at $177,566,000 after purchasing an additional 341,389 shares during the period. Acadian Asset Management LLC raised its stake in Bruker by 5.7% during the 4th quarter. Acadian Asset Management LLC now owns 5,229,258 shares of the medical research company’s stock worth $179,467,000 after buying an additional 280,245 shares during the period. Sensato Investors LLC raised its stake in Bruker by 57.0% during the 4th quarter. Sensato Investors LLC now owns 527,658 shares of the medical research company’s stock worth $18,109,000 after buying an additional 191,504 shares during the period. Mackenzie Financial Corp acquired a new stake in Bruker during the 4th quarter worth $6,142,000. Finally, Renaissance Technologies LLC raised its stake in Bruker by 105.7% during the 4th quarter. Renaissance Technologies LLC now owns 262,710 shares of the medical research company’s stock worth $9,016,000 after buying an additional 135,000 shares during the period. Institutional investors and hedge funds own 65.28% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Analysts Expect Bruker (BRKR) Will Announce Quarterly Sales of $418.11 Million” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/analysts-expect-bruker-brkr-will-announce-quarterly-sales-of-418-11-million.html.
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide. The company operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear and explosive detection in emergency response, homeland security, and defense applications; and analytical and process analysis instruments and solutions.
Get a free copy of the Zacks research report on Bruker (BRKR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.